Evaluation of Chinese hamster ovary cell stability during repeated batch culture for large-scale antibody production

Journal of Bioscience and Bioengineering

Volumn 109, Issue 3, 2010, Pages 274-280

  Kaneko, Yoshihiro ^a,b   Sato, Ryuji ^c   Aoyagi, Hideki ^b  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c Chugai Pharmaceutical Manufacturing Co Ltd   (Japan)

Author keywords

HM1.24 antigen; Monoclonal antibody; Recombinant CHO cell; Scaled down cell culture

Indexed keywords

ACTIVE INGREDIENTS; ANTIBODY PRODUCTION; CELL LINES; CELLULAR FUNCTION; CHINESE HAMSTER OVARY CELLS; CHO CELL; CULTIVATION PERIODS; HIGH DENSITY; HM1.24 ANTIGEN; IN-CELL; LONG TERM STABILITY; PHARMACEUTICAL MANUFACTURING PLANTS; PRACTICAL PRODUCTION; RECOMBINANT CHO CELL; REPEATED-BATCH CULTURE; SCALED-DOWN CELL CULTURE; SPECIFIC PRODUCTIVITY; SPINNER FLASKS; VIABLE CELLS;

ALLERGIES; ANTIGENS; BATCH CELL CULTURE; BOTTLES; CELL PROLIFERATION; MERGERS AND ACQUISITIONS; MONOCLONAL ANTIBODIES; SURFACE PLASMON RESONANCE;

CELL CULTURE;

HM1.24 ANTIGEN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY PRODUCTION; ARTICLE; BACTERIUM CULTURE; CELL DENSITY; CELL FUNCTION; CELL PROLIFERATION; CELL VIABILITY; CHO CELL; FEMALE; NONHUMAN; SPECIES CULTIVATION;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL CULTURE TECHNIQUES; CELL SURVIVAL; CHO CELLS; CRICETINAE; CRICETULUS; GENETIC ENHANCEMENT; PROTEIN ENGINEERING;

CRICETULUS GRISEUS;

EID: 76049103863     PISSN: 13891723     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbiosc.2009.09.044     Document Type: Article

References (25)

1. Sauer P.W., Burky J.E., Wesson M.C., Sternard H.D., and Qu L. A high-yielding, generic fed-batch cell culture process for production of recombinant antibodies. Biotechnol. Bioeng. 67 (2000) 585-597
2. Yang J.D., Lu C., Stasny B., Henley J., Guinto W., Gonzalez C., Gleason J., Fung M., Collopy B., Benjamino M., Gangi J., Hanson M., and Ille E. Fed-batch bioreactor process scale-up from 3-L to 2,500-L scale for monoclonal antibody production from cell culture. Biotechnol. Bioeng. 98 (2007) 141-154
3. Pavlou A.K., and Reichert J.M. Recombinant protein therapeutics-success rates, market trends and values to 2010. Nat. Biotechnol. 22 (2004) 1513-1519
4. Walsh G. Biopharmaceutical benchmarks. Nat. Biotechnol. 24 (2006) 769-776
5. Molowa D.T., and Mazanet R. The state of biopharmaceutical manufacturing. Biotechnol. Annu. Rev. 9 (2003) 285-302
6. Kamarck M.E. Building biomanufacturing capacity-the chapter and verse. Nat. Biotechnol. 24 (2006) 503-505
7. Barnes L.M., Bentley C.M., and Dickson A.J. Stability of Protein production from recombinant mammalian cells. Biotechnol. Bioeng. 81 (2003) 631-639
8. Ohtomo T., Sugamata Y., Ozaki Y., Ono K., Yoshimura Y., Kawai S., Koishihara Y., Ozaki S., and Tsuchiya M. Molecular cloning and characterisation of a surface antigen preferentially over-expressed on multiple myeloma cells. Biochem. Biophys. Res. Commun. 258 (1999) 583-591
9. Ozaki S., Kosaka M., Wakatsuki S., Abe M., Koishihara Y., and Matsumoto T. Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24. Blood 90 (1997) 3179-3186
10. Ono K., Ohtomo T., Yoshida K., Yoshimura Y., Kawai S., Koishihara Y., Ozaki S., Kosaka M., and Tsuchiya M. The humanized anti-HM1.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cytotoxicity. Mol. Immunol. 36 (1999) 387-395
11. Ozaki S., Kosaka M., Wakahara Y., Ozaki Y., Tsuchiya M., Koishihara Y., Goto T., and Matsumoto T. Humanized anti-HM1.24 antibody mediates myeloma cell toxicity that is enhanced by cytokine stimulation of effector cells. Blood 93 (1999) 3922-3930
12. Goto T., Kennel S.J., Abe M., Takashita M., Kosaka M., Solomon A., and Saito S. A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood 84 (1994) 1922-1930
13. Li L., Mi L., Qin J., Feng Q., Liu R., Yu X., Xu L., and Chen Z. Stability validation of seeding cell control parameters in large-scale hybridoma cell culture. Appl. Microbiol. Biotechnol. 70 (2006) 34-39
14. Michel M.-L., Sobczak E., Malpièce Y., Tiollais P., and Streeck R.E. Expression of amplified hepatitis B virus surface antigen genes in Chinese hamster ovary cells. Bio/Technology 3 (1985) 561-566
15. Pallavicini M.G., DeTeresa P.S., Rosette C., Gray J.W., and Wurm F.M. Effects of methotrexate on transfected DNA stability in mammalian cells. Mol. Cell. Biol. 10 (1990) 401-404
16. Kim S.J., Kim N.S., Ryu C.J., Hong H.J., and Lee G.M. Characterization of chimeric antibody producing CHO cells in the course of dihydrofolate reductase-mediated gene amplification and their stability in the absence of selective pressure. Biotechnol. Bioeng. 58 (1998) 73-84
17. Hammill L., Welles J., and Carson G.R. The gel microdrop secretion assay: identification of a low productivity subpopulation arising during the production of human antibody in CHO cells. Cytotechnology 34 (2000) 27-37
18. Frame K.K., and Hu W.-S. The loss of antibody productivity in continuous culture of hybridoma cells. Biotechnol. Bioeng. 35 (1990) 469-476
19. Lee G.M., Varma A., and Palsson B.O. Application of population balance model to the loss of hybridoma antibody productivity. Biotechnol. Prog. 7 (1991) 72-75
20. Chuck A.S., and Palsson B.O. Population balance between producing and nonproducing hybridoma clones is very sensitive to serum level, state of inoculum, and medium composition. Biotechnol. Bioeng. 39 (1992) 354-360
21. Bae S.W., Hong H.J., and Lee G.M. Stability of transfectomas producing chimeric antibody against the pre-S2 surface antigen of hepatitis B virus during a long-term culture. Biotechnol. Bioeng. 47 (1995) 243-251
22. Petersen J.F., McIntire L.V., and Papoutsakis E.T. Shear sensitivity of cultured hybridoma cells (CRL-8018) depends on mode of growth, culture age and metabolite concentration. J. Biotechnol. 7 (1988) 229-246
23. Kim N.S., Kim S.J., and Lee G.M. Clonal variability within dihydrofolate reductase-mediated gene amplified Chinese hamster ovary cells: stability in the absence of selective pressure. Biotechnol. Bioeng. 60 (1998) 679-688
24. Fann C.H., Guirgis F., Chen G., Lao M.S., and Piret J.M. Limitations to the amplification and stability of human tissue-type plasminogen activator expression by Chinese hamster ovary cells. Biotechnol. Bioeng. 69 (2000) 204-214
25. Barnes L.M., Bentley C.M., and Dickson A.J. Stability of recombinant protein production in the GS-NS0 expression system is unaffected by cryopreservation. Biotechnol. Prog. 19 (2003) 233-237